Bancel Stephane's Form 4 filing
Moderna, Inc. (MRNA) · filed Feb 16, 2024
- Accession no.
- 0001127602-24-005355
- Filed
- Feb 16, 2024
- Trade date
- Feb 14-16, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $2.34M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bancel StephaneCIK 0001443340 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2024 | Common Stock | AGrant or awardAcquired | +56,736 | $0.00 | $0 | 5,486,575 | Direct | |
| Feb 16, 2024 | Common Stock | SSaleDisposed | −26,351 | $88.88 | −$2,342,076.88 | 5,460,224 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.